Tuberculosis and HIV co-infection in Congolese children: risk factors of death

Olivier Mukuku1,*, Augustin Mulangu Mutombo2, Christian Ngama Kakisingi3, Jacques Mbaz Musung3, Stanislas Okitotosho Wembonyama2, Oscar Numbi Luboya1,2,4

1Department of Research, Institut Supérieur des Techniques Médicales, Lubumbashi, Democratic Republic of Congo, 2Department of Pediatrics, University of Lubumbashi, Lubumbashi, Democratic Republic of Congo, 3Department of Internal Medicine, University of Lubumbashi, Lubumbashi, Democratic Republic of Congo, 4Department of Public Health, University of Lubumbashi, Lubumbashi, Democratic Republic of Congo

*Corresponding author: Olivier Mukuku, Department of Research, Institut Supérieur des Techniques Médicales, Lubumbashi, Democratic Republic of Congo

Key words: Tuberculosis, HIV, Co-infection, Child, Mortality, Lubumbashi

Received: 22/04/2019 - Accepted: 18/08/2019 - Published: 27/08/2019

Abstract

Introduction: Human immunodeficiency virus (HIV) and tuberculosis (TB) are the leading causes of death from infectious disease worldwide. The prevalence of HIV among children with TB in moderate to high prevalence countries ranges between 10% and 60%. This study aimed to determine the prevalence of HIV infection among children treated for TB in Directly Observed Treatment Short-Course (DOTS) clinics in Lubumbashi and to identify risk of death during this co-infection. Methods: this is a cross-sectional study of children under-15, treated for tuberculosis from January 1, 2013 to December 31, 2015. Clinical, paraclinical and outcome data were collected in 22 DOTS of Lubumbashi. A statistical comparison was made between dead and survived HIV-infected TB children. We performed the multivariate analyzes and the significance level set at p-value <0.05. Results: a total of 840 children with TB were included. The prevalence of HIV infection was 20.95% (95% CI: 18.34-23.83%). The mortality rate was higher for HIV-infected children (47.73%) compared to HIV-uninfected children (17.02%) (p<0.00001). Age <5 years (aOR=6.50 [1.96-21.50]), a poor nutritional status (aOR=23.55 [8.20-67.64]), and a negative acid-fast bacilli testing (aOR=4.51 [1.08-18.70]) were associated with death during anti-TB treatment. Conclusion: TB and HIV co-infection is a reality in pediatric settings in Lubumbashi. High mortality highlights the importance of early management.

The Pan African Medical Journal. 2019;33:326. doi:10.11604/pamj.2019.33.326.18911

This article is available online at: http://www.panafrican-med-journal.com/content/article/33/326/full/

© Olivier Mukuku et al. The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

The most important chronic diseases affecting children in sub-Saharan Africa are tuberculosis (TB), Human Immunodeficiency Virus (HIV) infection and malnutrition. These three diseases often have similar clinical aspects or are frequently associated with the same patient. Globally, the epidemic of HIV infection has been accompanied by a serious epidemic of TB [1,2]. HIV infection is the main risk factor for tuberculosis because HIV promotes the progression of latent or recent infections of Mycobacterium tuberculosis into active disease and also increases the frequency of TB [2,3]. Both pathologies are the two leading causes of infectious disease deaths worldwide [4]. There are well-established epidemiological and biological synergies between HIV and TB, which influence the distribution, progression and outcomes of both infections. The HIV epidemic is a key factor in the resurgence of TB incidence worldwide and HIV is the pre-incident risk factor for TB development [2,4]. According to the latest global estimates, 36.9 million people are living with HIV, 70% of whom live in sub-Saharan Africa [5] and 1.7 billion people are affected by latent TB [6,7]. In 2017, UNAIDS estimated 1.8 million children under-15 living with HIV [5]. World Health Organization (WHO) estimated that 10% (1 million) of the 10.4 million new TB cases recorded in 2016 were children and 11% (1.2 million) of those with TB were HIV positive [6]. But specifically for children, there is limited data on the incidence of HIV infection among children with TB, and the information available is difficult to interpret because of problems with diagnosis, under-reporting and selection of the studied populations (hospitals rather than community) [4]. WHO estimates that HIV prevalence among children with TB in medium and high prevalence countries is between 10% and 60% [8,9] and varies with background rates of HIV infection [10].

HIV-TB co-infection has been well explored in adults in sub-Saharan Africa, but has so far been insufficiently studied in children because of the difficulty of establishing an accurate diagnosis of TB in children in particular by microscopy. It is considered a major public health problem, particularly in resource constrained settings like Democratic Republic of Congo (DRC). The DRC is among the 30 countries heavily affected by TB; it ranks eleventh in the world and third in Africa [6]. In 2016, estimates report 32,000 cases of all forms of TB in children under-15 [6]. HIV infection and tuberculosis are two major burdens whose control or elimination is a huge challenge for African states and their health services. The co-infection tuberculosis and HIV in children is distinguished by its particular aspects. Epidemiologically, it is a direct consequence of adult tuberculosis and reflects the transmission of the disease in the community. The often atypical clinical manifestations (extrapulmonary tuberculosis) and the bacteriological and anatomo-pathological diagnosis remain difficult [11,12].

In the DRC, the fight against TB is the task entrusted to the National Tuberculosis Program (NTP), it is part of the direction of the fight against the diseases. In order to achieve its various objectives, the NTP recommends an integrated approach to TB control activities in Primary Health Care (PHC) structures in line with the strategy for strengthening the health system. The structure that provides diagnosis and treatment for tuberculosis patients is called the Directly Observed Treatment Short-Course (DOTS) clinics. The DOTS is the functional unit of the NTP [13]. The objectives of this study are to determine the prevalence of HIV infection among all children treated for TB in DOTS clinics in Lubumbashi (DRC) and to identify risk of death during this co-infection.

Methods

We conducted a cross-sectional study. Our team collected data from the 22 DOTS in Lubumbashi, the capital of the Haut-Katanga Province in the DRC. The target patients were children under-15 admitted to the DOTS with a diagnosis of tuberculosis from January 1st, 2013 to December 31st, 2015. Of a total of 8699 TB patients in this period, 840 were under 15 years old. The children were classified into two groups according to their HIV status. A group of HIV-positive TB children and a group of HIV-negative TB children have been formed.

The HIV testing strategy was that proposed by national standards and guidelines [14]. This strategy recommends the use of two rapid tests namely, Determine™ HIV1/2 and Unigold™ HIV. In the event of a discrepancy in rapid tests, HIV infection was confirmed by an Enzyme-Linked Immunosorbent Assay (ELISA). For children under 18 months of age, the diagnosis of HIV infection was made by Polymerase Chain Reaction (PCR). The diagnosis of smear-positive pulmonary TB (PTB) was made if a patient met at least one of the following criteria according to the standard definitions of the NTP of DRC adopted from WHO [13,15,16]: Acid-fast bacilli (AFB) in at least two sputum samples, The presence of AFB in a sputum sample and X-ray compatible with active pulmonary TB or AFB in sputum specimen and positive sputum culture for Mycobacterium tuberculosis.
The diagnosis of smear-negative PTB was made if the patient met the following criteria [13,15,16]: radiographic signs compatible with active PTB, AFB negative in three sputum samples, Decision to treat the patient as PTB by the medical staff of the hospital where the patient was admitted, Ineffectiveness of non-specific antibiotic therapy and.

Diagnosis of extrapulmonary tuberculosis (EPTB) was based on fine needle aspiration cytology or biochemical analyses of cerebrospinal/pleural/ascitic fluid or histopathological examination or strong clinical evidence consistent with active EPTB, followed by a decision of a clinician to treat with a full course of antituberculosis chemotherapy [13,15,16]. We also included patients who were unable to produce appropriate sputum specimens but whose symptoms and clinical history were consistent with active TB. Patients with both PTB and EPTB have been classified as PTB in accordance with the definition of the WHO [15].

Demographic and clinical information was collected from medical records using a standardized data collection form. The following data were extracted from the records of each patient: age, sex, contagion with a known TB case, history of TB, presence or absence of BCG vaccine scar, and time to onset of symptoms before admission to the service. The following general and physical clinical signs were systematically recorded: asthenia, weight loss, anorexia, unexplained fever (>2 weeks) greater than or equal to 38°C, persistent cough (>2 weeks), weight-for-age z-score (WAz) ≤-2 SD and peripheral lymphadenopathy. The results of the direct tuberculosis bacillus test, as well as those of the hemogram and HIV serology of each patient at admission were also recorded. AFB was performed on sputum or gastric tube fluid from patients with pulmonary or mixed forms of tuberculosis on admission: a direct examination by the Ziehl-Neelsen technique and culture of mycobacteria on the Löwenstein-Jensen medium.

The results of tuberculosis treatment have been classified into six categories according to WHO definitions: cured, completed treatment, died, defaulted treatment, failure and transfer-out [15]. Children who were cured and those who had completed treatment were classified as having successful treatment (or having a favorable outcome) [13,15,17]. All information collected was analyzed using STATA 12 software. For each factor studied, the proportions were compared between groups of HIV-positive and HIV-negative TB children and between dead and survived HIV-infected TB children. Chi square test was used for comparison of percentages in univariate and multivariate analysis. The significance level of all observed differences was set at p<0.05.

This study was authorized by the medical ethic committee of the University of Lubumbashi and the Health authority of Haut-Katanga Province before data collection. Patient records/information was anonymized and de-identified prior to analysis to ensure confidentiality of individual patient information.

**Results**

A total of 840 children with TB were included, of whom 176 were HIV-infected, an HIV infection of 20.95% (95% CI: 18.34-23.83%). Table 1 presents the epidemiological data, clinics and laboratory investigations of the 840 TB children according to their HIV status. The history of anti-TB treatment, prolonged fever, and EPTB were significantly more common in HIV-infected children than in HIV-uninfected children (p<0.05). The positive TST was significantly lower in HIV-infected children than in HIV-uninfected children (56.82 vs 65.21%) (p=0.0399). The same is true for nutritional status, we noted that 45.45% of HIV-infected children had a weight-for-age z-score ≤-2 SD against 18.83% in HIV-uninfected children (p<0.00001). The anti-TB treatment outcomes of HIV-infected children included in this study were 75 (42.61%) favorable, 8 (4.55%) defaulted, 84 (47.73%) died, 5 (2.84%) failure, and 4 (2.27%) transferred out. The mortality rate was higher for HIV-infected children (47.73%, n=84) compared to HIV-uninfected children (17.02%, n=113) (p <0.00001). The frequency of favorable anti-TB treatment outcomes was higher for HIV-negative patients (76.50%, n=508) compared to HIV-positive patients (42.61%, n=75) (Table 2). Table 3 shows the risk factors for death in HIV-infected children. Statistical analysis showed that age ≤5 years (aOR=6.50 [1.96-21.50]), a z-score weight-for-age ≤-2 SD (aOR=23.55 [8.20-67.64]), and a negative acid-fast bacilli testing (aOR=4.51 [1.08-18.70]) were most closely associated with mortality during anti-TB treatment.

**Discussion**

This study found that the prevalence of HIV-TB co-infection among TB patients was 20.95%, which is higher as compared with 11.8% prevalence that was reported in Abidjan (Côte-d’Ivoire) by Sassan-
Murokro et al. [18]. This rate is lower than the 25.7% found in Bangui (Central African Republic) by Bobossi-Serengbe et al. [19], than the 35% recorded in Brazzaville (Republic of Congo) by Loufoua-Lemay et al. [20]. In South Africa, Madhi et al. [21] reported 42% HIV infection in all children treated for tuberculosis in Johannesburg and, Jeena et al. [22] found only 48% of those whose tuberculosis was confirmed bacteriologically in Durban. Estimated rates of HIV infection among TB children vary widely around the world, in part depending on whether the study is conducted in an area where HIV infection is endemic or not. This study showed the increased mortality risk for HIV-infected TB children as compared to HIV-uninfected TB children. A possible explanation is the higher clinical severity of disease at the admission [23].

This study found that HIV-infected children were more likely to have extrapulmonary forms that could also explain this high mortality in these children. This high mortality in HIV-infected children could be attributed to late diagnosis and delayed antiretroviral treatment (ART). In sub-Saharan Africa, HIV infection in the pediatric population is often diagnosed very late and especially in the course of the disease, and when ART starts late, the child’s immune system may already be seriously compromised [24]. Early pediatric HIV testing is not done because some parents / guardians rely only on their child’s apparent good health, and others believe that children infected during the perinatal period do not survive until the end of their childhood [24,25]. Nearly half of HIV-infected TB children died during anti-TB treatment. HIV-TB co-infection was significantly associated with death and this is consistent with previous studies elsewhere [26-28]. Lolekha found that HIV-infected TB children were 6.9 times more likely to die than HIV-negative children [29]. HIV contributes substantially to the burden of childhood TB. HIV-TB co-infection is frequently associated with multiple infections complicating diagnosis and treatment, leading to increased morbidity and mortality [26]. Biruk et al. [30] explains that this would be related to pill burden, increase in adverse effect, drug-to-drug interaction, and immune reconstitution inflammatory syndrome.

In this study, a number of factors associated with death in HIV-infected TB children have been reported. The mortality rate among children under-5 was significantly higher than those over 5 years old. Our results corroborate those of studies elsewhere [26,31]. In line with this finding, a study in Malawi found a decline in death rates with advanced age [32]. Younger children, especially those younger than two years of age, are at increased risk of death from infectious diseases, including tuberculosis due to the immaturity of the immune system. In addition, these young children are frequently affected by disseminated tuberculosis and tuberculous meningitis, which are associated with high mortality [12,33,34].

In this observation, the characteristics of HIV-infected TB children associated with death during anti-TB treatment were being negative AFB testing. Previous studies reported that TB patients with unsuccessful treatment outcome were being smeared negative pulmonary TB [35-39]. This could be due to the treatment outcome monitoring of smear-positive TB patients who, apart from clinical progression, have repeated sputum tests [30]. Contrary to our findings, Bloss et al. [40] and Hailu et al. [26] found that children with smear-positive PTB died more than those with smear-negative smears and assume that it is related to late-stage TB in the majority of patients in their series.

Our study showed that 82.19% of the dead children had a poor nutritional status. We observed a significant correlation between nutritional deficit and mortality in HIV-infected TB children. A nutritional deficit and a lower concentration of serum albumin have been found to be important risk factors for mortality in TB patients in previous studies [41,42]. According to Kim, malnutrition would be a clinical finding reflecting the severity of TB and the determinant of mortality would be the severity of TB rather than malnutrition itself [42].

**Limitations of the Study**

Therefore, this study is not without limits and the results of this study should be interpreted with the following limitations. The major limitation of this work is the use of retrospective data, which is totally restricted to what is documented in the TB registers. Predictor variables which might affect outcome like treatment adherence level, comorbidities, modalities of HIV care and ART usage, other opportunistic infections as well as behavioral and social factors, were not available in the TB national system.

**Conclusion**

High proportion of death in HIV-infected TB children was documented in this study. Moreover, the following risk factors were identified as predictors of death: age ≤ 5 years, poor nutritional status, and negative AFB testing. Based on the findings of this study, we...
recommend that emphasis has to be given for children with high risk of death and targeted interventions should be carried out.

**What is known about this topic**
- In the DRC, infectious disease are a major public health problem with an important rate of morbidity and mortality among children;
- Mortality due to TB and HIV on young children is separately higher.

**What this study adds**
- In this study, the incidence of HIV among children with TB is 20.95% and children with HIV-TB coinfection had a higher mortality rate as compared to the HIV uninfected children with TB;
- The proposed study is the first study in our setting, integrating a multivariate analysis to identify the risk factors of death in HIV-infected TB children in Lubumbashi, Democratic Republic Congo;
- In our environment, the risk factors of death for TB- and HIV co-infection on children are: age ≤5 years, poor nutritional status, and negative AFB testing.

### Competing interests

The authors declare no competing interests.

### Authors’ contributions

OM, AMM, CNK, JMM and ONL conceived, designed, deployed and directed the study. OM and AMM sample collection, storage and transport. OM and CNK wrote the manuscript. SOW and ONL brought some precious corrections. OM analyzed data. OM and CNK edited the English and made corrections. All authors read and approved the final manuscript.

### Acknowledgements

The authors gratefully thank Professors Alan Whiteside and Tim Quinlan for editing this manuscript.

### Tables

- **Table 1**: participants characteristics
- **Table 2**: anti-TB treatment outcomes among 840 TB children in Lubumbashi
- **Table 3**: risk factors for death in HIV infected children

### References

1. Newton SM, Brent AJ, Anderson S, Whittaker E, Kampmann B. Paediatric tuberculosis. *Lancet Infect Dis*. 2008;8(8):498-510. PubMed | Google Scholar

2. Pawlowski A, Jansson M, Sköld M, Rottenberg ME, Källenius G. Tuberculosis and HIV Co-Infection. *PLoS Pathogens*. 2012;8(2):e1002464. PubMed | Google Scholar

3. Marais BJ, Gie RP, Schaaf HS, Beyers N, Donald PR, Starke JR. Childhood pulmonary tuberculosis: old wisdom and new challenges. *Am J Respir Crit Care Med*. 2006;173(10):1078-90. PubMed | Google Scholar

4. Marais BJ, Graham SM, Cotton MF, Beyers N. Diagnostic and management challenges of childhood tuberculosis in the era of HIV. *J Infect Dis* 2007; 196 Suppl 1: S76-85. PubMed | Google Scholar

5. UNAIDS. UNAIDS DATA 2018. 2018. Accessed on 22 April 2019.

6. WHO. Global tuberculosis report 2017. Geneva: World Health Organization, 2017. Google Scholar

7. Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. *PLoS Med*. 2016;13(10):e1002152. PubMed | Google Scholar

8. Hesseling AC, Cotton MF, Jennings T, Whitelaw A, Johnson LF, Eley B et al. High incidence of tuberculosis among HIV-infected infants: evidence from a South African population-based study highlights the need for improved tuberculosis control strategies. *Clin Infect Dis* 2009;48(1):108-14. PubMed | Google Scholar
9. Venturini E, Turkova A, Chiappini E, Galli L, de Martino M, Thorne C. Tuberculosis and HIV co-infection in children. BMC Infectious Diseases 2014;14(Suppl 1):S5. PubMed | Google Scholar
10. Walters E, Cotton MF, Rabie H, Schaaf HS, Walters LO, Marais BJ. Clinical presentation and outcome of tuberculosis in human immunodeficiency virus infected children on antiretroviral therapy. BMC Pediatrics 2008;8:1. PubMed | Google Scholar
11. Jurcev-Savicevic A, Mulic R, Klismanic Z, Katalinic-Jankovic V. Childhood tuberculosis: an ancient disease in the youngest generation in 21st century from epidemiological point of view. Acta Med Croatica. 2011;65(1):3-10. PubMed | Google Scholar
12. Swaminathan S, Rekha B. Pediatric tuberculosis: global overview and challenges. Clin Infect Dis 2010;15(Suppl 3):184-94. PubMed | Google Scholar
13. Ministry of Health (DRC). National Tuberculosis Program; tuberculosis management guide. Kinshasa: PATI IV;2008:22-5.
14. Ministry of Health (DRC). National Program against AIDS and STIs. Standards and guidelines for HIV/AIDS voluntary counseling and testing. Kinshasa: PNLS; 2004.
15. WHO. Guidance for national tuberculosis programs on the management of tuberculosis in children. 2nd ed. Geneva: World Health Organization; 2014.
16. Kakisingi C, Mukuku O, Kajimp B, Manika M, Beya T, Kibulungu C et al. Treatment outcome of Tuberculosis patients with HIV under directly observed treatment short course (DOTS) in Lubumbashi (DR Congo). J Infectious Disease Med Microbiol. 2018;2(2):5-10. Google Scholar
17. Pefura Yone EW, Evouna Mbarga A, Kuaban C. Impact of HIV infection on childhood tuberculosis in Yaounde, Cameroon. Rev Mal Respir. 2012;29(9):1095-103. PubMed | Google Scholar
18. Sassan-Moroko M, De Cock KM, Ackah A, Vetter KM, Doorly R, Brattegaard K et al. Tuberculosis and HIV infection in children in Abidjan, Côte d'Ivoire. Trans R Soc Trop Med Hyg 1994;88:178-81. PubMed | Google Scholar
19. Bobossi-Serengbe G, Tembeti PJ, Mobina T, Yango F, Kassa-Kelembo E. Tuberculosis and HIV co-infection among children hospitalized in Bangui (Central African Republic). Archives de pédiatrie. 2005;12(8):1215-1220. PubMed | Google Scholar
20. Loufoua-Lemay AM, Youndouka JM, Pambou B, Nzingoula S. La tuberculose chez l'enfant au CHU de Brazzaville de 1995 à 2003. Bull Soc Pathol Exot, 2008;101(4):303-307. Google Scholar
21. Madhi SA, Hubeiner RE, Doedens L, Aduc T, Wesley D, Cooper PA. HIV-1 co-infection in children hospitalised with tuberculosis in South Africa. Int J Tuberc Lung Dis. 2000;4(5):448-54. PubMed | Google Scholar
22. Jeena PM1, Pillay P, Pillay T, Coovadia HM. Impact of HIV-1 co-infection on presentation and hospital-related mortality in children with culture proven pulmonary tuberculosis in Durban, South Africa. Int J Tuberc Lung Dis. 2002;6(8):672-8. PubMed | Google Scholar
23. Schmaltz CAS, Sant’Anna FM, Neves SC, Velasque LS, Lourenco MC et al. Influence of HIV infection on mortality in a cohort of patients treated for tuberculosis in the context of wide access to HAART, in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr. 2009;52(5):623-8. PubMed | Google Scholar
24. Ngwej DT, Mukuku O, Malonga FK, Luboya ON, Kakoma JS, Wembonyama SO. Seroprevalence and factors associated with Voluntary Counselling and Testing (VCT) for HIV among children in Lubumbashi, Democratic Republic of the Congo. Pan Afr Med J. 2017;28:8. PubMed | Google Scholar
25. Davies MA, Kalk E. Provider-initiated HIV testing and counselling for children. PLoS Med. 2014;11(5):e1001650. PubMed | Google Scholar
26. Hailu D, Abegaz WE, Belay M. Childhood tuberculosis and its treatment outcomes in Addis Ababa: a 5-years retrospective study. BMC Pediatr. 2014;14:61. PubMed | Google Scholar
27. Oeltmann JE, Chengeta B, Mboya JJ, Wells CD, Kilmarx PH, Samandari T et al. Reported childhood tuberculosis treatment outcomes, Gaborone and Francistown, Botswana, 1998-2002. Int J Tuberc Lung Dis. 2008;12(2):186-192. PubMed | Google Scholar
28. Mukadi YD, Wiktor SZ, Coulibaly I, Coulibaly D, Mbengue A, Folquet AM et al. Impact of HIV infection on the development, clinical presentation, and outcome of tuberculosis among children in Abidjan, Côte d'Ivoire. AIDS. 1997;11(9):1151-8. PubMed | Google Scholar

29. Lolekha R, Anuwatnonthakate A, Nateniyom S, Sumnapun S, Yamada N, Wattanaamornkiet W et al. Childhood TB epidemiology and treatment outcomes in Thailand: a TB active surveillance network, 2004-2006. BMC Infect Dis. 2008;8:94. PubMed | Google Scholar

30. Biruk M, Yimam B, Abrha H, Biruk S, Amdie FZ. Treatment outcomes of tuberculosis and associated factors in an Ethiopian University Hospital. Advances in Public Health. 2016;2016:Article ID 8504629:9. Google Scholar

31. Wu XR, Yin QQ, Jiao AX, Xu BP, Sun L, Jiao WW et al. Pediatric tuberculosis at Beijing Children's Hospital: 2002-2010. Pediatrics. 2012;130(6):e1433-40. PubMed | Google Scholar

32. Tweya H, Feldacker C, Phiri S, Ben-Smith A, Fenner L, Jahn A, Kalulu M, Weigel R, Kamba C, Banda R, Egger M, Keiser O. Comparison of treatment outcomes of New smear-positive pulmonary tuberculosis patients by HIV and antiretroviral status in a TB/HIV clinic, Malawi. PLoS One. 2013;8(2):e56248. PubMed | Google Scholar

33. Nelson LJ, Wells CD. Global epidemiology of childhood tuberculosis. Int J Tuberc Lung Dis. 2004;8(5):636-647. PubMed | Google Scholar

34. Enarson PM, Enarson DA, Gie R. Management of tuberculosis in children in low-income countries. Int J Tuberc Lung Dis. 2005;9(12):1299. PubMed | Google Scholar

35. Satyanarayana S, Shivashankar R, Vashist RP, Chauhan LS, Chadha SS, Dewan PK et al. Characteristics and programme-defined treatment outcomes among childhood tuberculosis (TB) patients under the national TB programme in Delhi. PLoS One. 2010;5(10):e13338. PubMed | Google Scholar

36. Munoz-Sellart M, Yassin MA, Tomato M, Merid Y, Cuevas LE. Treatment outcome in children with tuberculosis in Southern Ethiopia. Scand J Infect Dis. 2009;41(6-7):450-455. PubMed | Google Scholar

37. Mtabho CM, Ironto MJ, Boeree MJ, Aarnoutse RE, Kibiki GS. Childhood Tuberculosis in the Kilimanjaro region: lessons from and for the TB Programme. Trop Med Int Health. 2010;15(5):496-501. PubMed | Google Scholar

38. Munoz-Sellart M, Cuevas LE, Tomato M, Merid Y, Yassin MA. Factors associated with poor tuberculosis treatment outcome in the Southern Region of Ethiopia. The International Journal of Tuberculosis and Lung Disease. 2010;14(8):973-979. PubMed | Google Scholar

39. Biadglegne F, Anagaw B, Debebe T, Anagaw B, Tesfaye W, Tessema B et al. A retrospective study on the outcomes of tuberculosis treatment in Felege Hiwot Referral Hospital, Northwest Ethiopia. International Journal of Medicine and Medical Sciences. 2013;5(2):85-91. Google Scholar

40. Bloss E, Chan PC, Cheng NW, Wang KF, Yang SL, Cegielski P. Increasing directly observed therapy related to improved tuberculosis treatment outcomes in Taiwan. Int J Tuberc Lung Dis. 2012;16(4):462-467. PubMed | Google Scholar

41. Hanrahan CF, Golub JE, Mohapi L, Tshabangu N, Modisenyane T, Chaisson RE et al. Body mass index and risk of tuberculosis and death. AIDS. 2010;24(10):1501-1508. PubMed | Google Scholar

42. Kim HJ, Lee CH, Shin S, Lee JH, Kim YW, Chung HS et al. The impact of nutritional deficit on mortality of in-patients with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2010;14(1):79-85. PubMed | Google Scholar
### Table 1: participants characteristics

| Variable | Total, n (%) (N=840) | HIV-infected, n (%) (n=176) | HIV-uninfected, n (%) (n=664) | p |
|----------|-----------------------|-----------------------------|-------------------------------|---|
| Age ≤5 years | 202 (24.05) | 46 (26.14) | 156 (23.49) | 0.5286 |
| Mean age ± SD (years) | 8.27±3.95 | 8.30±3.92 | 8.16±4.08 | 0.6767 |
| Male sex | 438 (52.14) | 89 (50.57) | 349 (52.56) | 0.6998 |
| Absence of BGC vaccine scar | 120 (14.29) | 22 (12.50) | 98 (14.76) | 0.5219 |
| History of contact with a smear-positive TB patient | 595 (70.83) | 128 (72.73) | 467 (70.33) | 0.5971 |
| Re-treatment | 57 (6.79) | 36 (20.45) | 21 (3.16) | <0.00001 |
| Fever ≥2 weeks | 615 (73.21) | 140 (79.55) | 475 (71.54) | 0.0415 |
| Cough ≥2 weeks | 463 (55.12) | 99 (56.25) | 364 (54.82) | 0.7994 |
| Lymphadenopathy | 380 (45.24) | 79 (44.89) | 301 (45.33) | 0.9838 |
| Anorexia | 580 (69.05) | 124 (70.91) | 456 (68.67) | 0.7170 |
| Weight loss | 547 (65.12) | 123 (69.89) | 424 (63.86) | 0.1604 |
| Night sweats | 376 (44.76) | 72 (40.91) | 304 (45.78) | 0.2842 |
| Poor nutritional status (WAZ ≤ -2 SD) | 205 (24.40) | 80 (45.45) | 125 (18.83) | <0.00001 |
| EPTB | 123 (14.64) | 37 (21.02) | 86 (12.95) | 0.0100 |
| TST positive | 533 (63.45) | 100 (56.82) | 433 (65.21) | 0.0399 |
| AFB positive | 201 (24.00) | 34 (24.46) | 167 (25.36) | 0.3475 |

HIV: human immunodeficiency virus; SD: standard deviation; TB: tuberculosis; TST: Tuberculin skin test; AFB: Acid Fast Bacilli; WAZ: Weight-for-Age Z-score; EPTB: Extra pulmonary tuberculosis

### Table 2: anti-TB treatment outcomes among 840 TB children in Lubumbashi

| Anti-TB treatment outcomes | Total, n (%) (N=840) | HIV-infected, n (%) (n=176) | HIV-uninfected, n (%) (n=664) | p |
|---------------------------|-----------------------|-----------------------------|-------------------------------|---|
| Successful treatment *    | 583 (69.40) | 75 (42.61) | 508 (76.50) | 0.00001 |
| Died                      | 197 (23.45) | 84 (47.73) | 113 (17.02) | 0.00001 |
| Failure                   | 15 (1.79) | 5 (2.84) | 10 (1.51) | 0.3057 |
| Defaulted                 | 32 (3.81) | 8 (4.55) | 24 (3.61) | 0.3057 |
| Transferred out           | 13 (1.55) | 4 (2.27) | 9 (1.36) | 0.3057 |

*Cured + Completed treatment
Table 3: risk factors for death in HIV infected children

| Variable                      | Total (N=159) | Died, n (%) (n=84) | Survived, n (%) (n=75) | Crude OR [95% CI] | Adjusted OR [95% CI] |
|-------------------------------|---------------|--------------------|------------------------|-------------------|--------------------|
| **Age ≤5 years**              |               |                    |                        |                   |                    |
| Yes                           | 36            | 27 (75.00)         | 9 (25.00)              | 3.47 [1.51-7.99]  | 6.50 [1.96-21.50]  |
| No                            | 123           | 57 (46.34)         | 66 (53.66)             | 1.00              | 1.00               |
| **Sex**                       |               |                    |                        |                   |                    |
| Male                          | 81            | 43 (53.09)         | 38 (46.91)             | 1.02 [0.54-1.90]  | 0.98 [0.41-2.31]   |
| Female                        | 78            | 41 (52.56)         | 37 (47.44)             | 1.00              | 1.00               |
| **Re-treatment**              |               |                    |                        |                   |                    |
| Yes                           | 34            | 22 (64.71)         | 12 (35.29)             | 1.86 [0.85-4.08]  | 1.27 [0.37-4.39]   |
| No                            | 125           | 62 (49.60)         | 63 (50.40)             | 1.00              | 1.00               |
| **History of TB contact**     |               |                    |                        |                   |                    |
| Yes                           | 116           | 62 (53.45)         | 54 (46.55)             | 1.09 [0.54-2.20]  | 1.32 [0.49-3.54]   |
| No                            | 43            | 22 (51.16)         | 21 (48.84)             | 1.00              | 1.00               |
| **BGC vaccine scar**          |               |                    |                        |                   |                    |
| Yes                           | 20            | 12 (60.00)         | 8 (40.00)              | 1.39 [0.53-3.62]  | 1.84 [0.45-7.42]   |
| No                            | 139           | 72 (51.80)         | 67 (48.20)             | 1.00              | 1.00               |
| **Anorexia**                  |               |                    |                        |                   |                    |
| Yes                           | 113           | 62 (54.87)         | 51 (45.13)             | 1.32 [0.66-2.63]  | 1.04 [0.38-2.82]   |
| No                            | 46            | 22 (47.83)         | 24 (52.17)             | 1.00              | 1.00               |
| **Night sweats**              |               |                    |                        |                   |                    |
| Yes                           | 62            | 28 (45.16)         | 34 (54.84)             | 0.60 [0.32-1.14]  | 0.88 [0.34-2.28]   |
| No                            | 97            | 56 (57.73)         | 41 (42.27)             | 1.00              | 1.00               |
| **Weight loss**               |               |                    |                        |                   |                    |
| Yes                           | 112           | 61 (54.46)         | 51 (45.54)             | 1.25 [0.63-2.47]  | 1.42 [0.51-3.92]   |
| No                            | 47            | 23 (48.94)         | 24 (51.06)             | 1.00              | 1.00               |
| **Poor nutritional status**   |               |                    |                        |                   |                    |
| Yes                           | 73            | 60 (82.19)         | 13 (17.81)             | 11.92 [5.56-25.56]| 23.55 [8.20-67.64] |
| No                            | 86            | 64 (72.09)         | 22 (27.91)             | 1.00              | 1.00               |
| **Fever >2 weeks**            |               |                    |                        |                   |                    |
| Yes                           | 130           | 67 (51.54)         | 63 (48.46)             | 0.75 [0.33-1.69]  | 0.69 [0.23-2.06]   |
| No                            | 29            | 17 (58.62)         | 12 (41.38)             | 1.00              | 1.00               |
| **Cough >2 weeks**            |               |                    |                        |                   |                    |
| Yes                           | 87            | 38 (43.68)         | 49 (56.32)             | 1.00              | 1.00               |
| No                            | 72            | 46 (63.89)         | 26 (36.11)             | 2.28 [1.20-4.33]  | 0.53 [0.19-1.47]   |
| **Lymphadenopathy**           |               |                    |                        |                   |                    |
| Yes                           | 71            | 39 (54.93)         | 32 (45.07)             | 1.16 [0.62-2.18]  | 1.37 [0.54-3.45]   |
| No                            | 88            | 45 (51.14)         | 43 (48.86)             | 1.00              | 1.00               |
| **Type of TB**                |               |                    |                        |                   |                    |
| EPTB                          | 36            | 23 (63.89)         | 13 (36.11)             | 1.79 [0.83-3.87]  | 1.42 [0.35-4.76]   |
| PTB                           | 123           | 61 (49.59)         | 62 (50.41)             | 1.00              | 1.00               |
| **TST**                       |               |                    |                        |                   |                    |
| Negative                      | 68            | 38 (55.88)         | 30 (44.12)             | 1.24 [0.66-2.32]  | 0.39 [0.15-1.01]   |
| Positive                      | 91            | 46 (50.55)         | 45 (49.45)             | 1.00              | 1.00               |
| **AFB testing**               |               |                    |                        |                   |                    |
| Positive                      | 30            | 9 (30.00)          | 21 (70.00)             | 1.00              | 1.00               |
| Negative                      | 129           | 75 (58.14)         | 54 (41.86)             | 3.24 [1.37-7.62]  | 4.51 [1.08-18.70]  |

HIV: human immunodeficiency virus; SD: standard deviation; TB: tuberculosis; TST: Tuberculin skin test; AFB: Acid Fast Bacilli; WAZ: Weight-for-Age Z-score; EPTB: Extra pulmonary tuberculosis; PTB: Pulmonary tuberculosis; OR: odds ratio; 95% CI: 95% confidence interval